Welcome to our dedicated page for Scinai Immunotherapeutics news (Ticker: SCNI), a resource for investors and traders seeking the latest updates and insights on Scinai Immunotherapeutics stock.
Scinai Immunotherapeutics Ltd. reports developments as a Nasdaq-listed biopharmaceutical issuer with American Depositary Shares and a dual model spanning inflammation and immunology R&D and contract development and manufacturing services. Its updates cover the PC111 monoclonal antibody program targeting soluble Fas Ligand for severe dermatological and autoimmune conditions, next-generation NanoAb-based programs, and development rights or research funding tied to its immunology pipeline.
Company news also covers the CDMO platform operated through Scinai Biopharma Services Ltd., including the completed acquisition of Recipharm Israel, manufacturing capabilities across biologics and small-molecule programs, customer service expansion, operating results, material agreements, shareholder matters, capital-structure disclosures, and Nasdaq listing compliance for its ADSs.
Scinai Immunotherapeutics (NASDAQ: SCNI) announced that its CDMO subsidiary, Scinai Biopharma Services, has appointed Eran Kuratz as Head of Supply Chain and Business Process Administration, reporting to CEO Amir Reichman. Kuratz brings over 30 years of leadership in supply chain and operations across pharmaceutical, biotechnology, medical-device and industrial companies, including senior roles at Kamada, Gamida Cell, OdysightAI, Elite PepsiCo-Frito-Lay and EnvyHer.
In his new role, he oversees supply chain and operational support functions such as procurement and contracting, warehousing, logistics, inventory management, budgeting and cost control, bookkeeping administration, and IT and business systems, including ERP, CRM, quality-management platforms and cybersecurity. According to the company, this appointment supports integration and scale-up following the first-quarter 2026 acquisition of Recipharm Israel, which added a Yavne site complementing the Jerusalem biologics facility and expanded Scinai’s CDMO capacity and technical capabilities.
Scinai (NASDAQ:SCNI) reported Q1 2026 revenue of $489 thousand versus $586 thousand in Q1 2025, with $200 thousand from the newly acquired Yavne CDMO site. Operating loss was $2.5 million, while net income reached $3.6 million driven by a $6.2 million bargain purchase gain.
Scinai completed the Recipharm Israel acquisition, adding a second manufacturing site and $6.2 million of net identifiable assets, and is advancing non-dilutive grant applications to support the PC111 antibody and IL-17 bispecific NanoAb programs and CDMO expansion.
Scinai Immunotherapeutics (NASDAQ: SCNI) announced that subsidiary Scinai Biopharma Services has appointed Eilon Elmalem as Site Head of its Yavne CDMO facility, effective June 14, 2026. He assumes responsibility for site operations and engineering, following a transition supervised by current site head Dr. Sylvia Kachalsky, who plans to retire later in 2026.
Elmalem has over 20 years of biotechnology and pharmaceutical leadership experience, including senior roles at Merck and Sigma-Aldrich Millipore, with a background in GMP facility expansion, capital programs, and complex organizational transformations.
Scinai Immunotherapeutics (NASDAQ: SCNI) will lead a strategic roundtable at the 7th Dermatology Drug Development Summit Europe in Amsterdam.
The session, led by CEO Amir Reichman and Dr. Meital Portugal, will examine how oral peptides and small molecules may complement or compete with biologic therapies in immunology and dermatology.
Scinai (NASDAQ: SCNI) announced a private placement and warrant inducement expected to close on or about April 27, 2026, raising approximately $2.61 million gross before fees and expenses. The financing includes 5,208,333 ADSs at $0.48 per ADS and two warrant series exercisable at $0.48 and $0.55.
The company said net proceeds will support expansion of its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. A.G.P./Alliance Global Partners served as sole financial advisor.
Scinai (NASDAQ: SCNI) completed a strategic reorganization on April 6, 2026, creating a dedicated CDMO subsidiary, Scinai Biopharma Services, following its February 2026 acquisition of Recipharm Israel (Yavne site). The move separates CDMO operations from a leaner R&D-focused Scinai Immunotherapeutics and targets ~$5 million in CDMO revenues for 2026.
The CDMO platform combines Jerusalem biologics capabilities, Yavne small-molecule/API capacity, and a commercial collaboration with Recipharm that provides subcontracting access and referral-based royalties.
Scinai (NASDAQ: SCNI) reported full-year 2025 results with CDMO revenues doubling to $1.3 million and a year-end cash position of $1.8 million. Net loss was $8.3 million, driven in part by the absence of 2024 financial income. Post‑year-end, Scinai acquired Recipharm Israel and signed a strategic collaboration to expand CDMO capabilities into small‑molecule manufacturing. The company resubmitted a FENG grant request that could provide up to €12 million in funding matched by ~€3 million company investment.
Scinai Immunotherapeutics (Nasdaq: SCNI) will attend BIO-Europe Spring 2026 in Lisbon March 23–25, showcasing its expanded CDMO platform and antibody-based immunology pipeline following the acquisition of Recipharm Israel and a strategic collaboration with Recipharm.
Highlights: integrated cGMP biologics site in Jerusalem, acquired cGMP small-molecule API site in Yavne, a client "graduation" model from early development to commercial supply, and a dermatology-focused antibody pipeline licensed from Max Planck, University Medical Center Göttingen, and PinCell.
Scinai Immunotherapeutics (Nasdaq: SCNI) said it received a Nasdaq written notice dated March 12, 2026, for noncompliance with the Nasdaq Capital Market minimum $1.00 bid price rule after ADSs closed below $1.00 for 30 consecutive business days.
The notice does not affect current listing or trading and provides an initial 180-calendar-day compliance period through September 8, 2026 to regain the $1.00 minimum by achieving at least ten consecutive business days at or above $1.00. The company said it will monitor the ADS closing price and evaluate options to regain compliance.
Scinai (Nasdaq: SCNI) executed a Second Amendment to its PinCell option agreement and submitted a revised €12 million non-dilutive FENG SMART Path application to support a €15 million integrated R&D program for PC111, a fully human anti-sFasL antibody for PV and SJS/TEN.
The amendment extends option condition deadlines to August 31, 2026 and the exercise period to September 30, 2026. A funding decision is expected in approximately three to four months.